Background: Cohen syndrome is a rare autosomal recessive inherited disorder that results
INTRODUCTION
Cohen syndrome (CS) (OMIM 216550) is a rare autosomal recessive disorder first described in 1973, which involves a broad spectrum of clinical manifestations. 1 Based on the observations of 29 Finish patients with CS, Kivitie-Kallio and Norio 2 were the first to propose the essential features for CS diagnosis prior to the identification of the COH1 gene: (1) nonprogressive mental retardation, motor clumsiness, and microcephaly; (2) typical facial features including wave shaped eyelids, short philtrum, thick hair, and low hairline; (3) childhood hypotonia and joint hyperextensibility; (4) retinochoroidal dystrophy and myopia by 5 years of age; (5) periods of isolated neutropenia. These criteria were modified by
Chandler et al 3 to be more applicable to young patients, when there is not yet evidence of chorioretinal dystrophy (CRD) or patients with a more heterogeneous genetic background.
These authors proposed that CS could be diagnosed in the presence of at least two of the following major criteria in a child with significant learning difficulties: (1) facial gestalt, characterised by thick hair, eyebrows and eyelashes, wave shaped, downward slanting palpebral fissures, prominent, beak-shaped nose, short, upturned philtrum with grimacing expression on smiling; (2) pigmentary retinopathy; (3) neutropenia (defined as < 2000/mm3).
The VPS13B gene was subsequently identified on chromosome 8q22-q23. This gene is composed of 62 exons that span a genomic region of around 864 kb and encodes a putative transmembrane protein of 4,022 amino acids with a complex domain structure (OMIM 607817). 4 Although the exact function of VPS13B protein remains unknown, homology to the Saccharomyces cerevisiae VPS13 protein suggests a role in vesicle-mediated sorting and intracellular protein trafficking. 4 Since the first identification of a VPS13B gene mutation, 4 more than a hundred distinct VPS13B gene mutations have been identified [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] Given the increasing number of requests for molecular testing in patients with suspected CS and the very large size of the gene, the aim of our study was to determine which of the above clinical features are the best indicators for the presence of VPS13B gene mutations by comparing patients carrying VPS13B mutations with negative patients in a series of 34 patients referred for molecular testing of VPS13B in suspected CS. The results should help clinicians to evaluate whether VPS13B mutations are likely to be responsible for a clinical phenotype combining a number of features. We also evaluated the current diagnostic criteria. only between twenty and thirty bases inside the intervening sequences donor site and acceptor site from the consensus splice junction sequences are clearly investigated by the sequencing analysis program and subjected to alignment with the reference sequence. Mutation nomenclature 16 numbering was based on the current Ensembl transcript (Ensembl Transcript ID ENST00000358544), with +1 as the A of the ATG initiation codon. Mutations leading to premature truncations were considered pathogenic. When a missense mutation was found, its absence was verified in 220 control chromosomes.
SUBJECTS AND METHODS

Subjects
Statistical analyses
The proportion of clinical features of the CS spectrum in the group of patients with VPS13B
gene mutations was compared with that in the group of patients with negative VPS13B
sequencing, using Fisher's exact test. These analyses were possible because the age at molecular screening in the two groups was similar.
RESULTS
Clinical description
Patients with VPS13B mutations VPS13B mutations were found in 12 patients (7 males and 5 females) originating from 8 families ( 
Patients without a VPS13B mutation
The 22 patients (7 males, 15 females) in whom no VPS13B gene mutation was found originated from 21 families, of which 1 was consanguineous. The mean age at molecular screening was 15.8±7.7 years. The percentages of clinical features of the CS spectrum are reported in Table 1 . In particular, CRD was observed in 6/19 ascertained patients. One patient had neutropenia. Kolehmainen's criteria for CS were fulfilled in 5/22. Table 2 summarizes the mutations found in this series as well as the predicted consequence of each mutation at the protein level. A total of 14 different mutations, of which 11 have never been published, were identified in the 8 families. All mutations except 3 resulted in premature truncation ( Table 2) . One patient had, on the same allele on exon 56, a missense mutation figure 2) , iv) the absence of this variant in 100 healthy controls. Only one truncating heterozygous VPS13B mutation was found in two patients, but these patients were considered as having CS in the presence of the typical clinical picture of the condition.
8
VPS13B gene mutations
Statistical analyses
Significant differences were found between the group of patients with VPS13B mutations and the group of patients without VPS13B mutations. Indeed, the probability of finding CRD, neutropenia, microcephaly and myopia was higher in the group of patients with VPS13B mutations (Table 1) . Conversely, there was no significant difference for the presence of facial gestalt, narrow extremities and truncal obesity. In this series, the sensitivity of CDR and neutropenia was 92% for both parameters whilst specificity was 68% and 95%, respectively.
DISCUSSION
The hallmarks of CS include mental retardation, facial dymorphism, chorioretinal dystrophy and neutropenia, and patients exhibit high clinical homogeneity. Following identification of the VPS13B gene, it was discovered that patients with VPS13B mutations, who did not fulfil CS clinical criteria were exceptional. [4] [5] [6] [7] [8] [9] [10] [11] [12] Contrary to other examples in the literature 17 , the identification of the VPS13B gene has not made it possible to enlarge the clinical spectrum of CS. On the contrary, patients with suspected CS based on the presence of evocative facial gestalt but in the absence of ophthalmologic manifestations were reclassified as having
Cohen-like syndrome, since no VPS13B mutations were found on either allele. 8 Only
Kolehmainen et al 7 has given a brief description of patients negative for VPS13B mutations.
The aim of this study was to compare the clinical features of patients with VPS13B mutations with those in patients without VPS13B mutations in order to give clues to the clinician on the indication for VPS13B screening according to the clinical phenotype, especially since molecular screening of VPS13B is a time-consuming task. We showed that all patients with VPS13B mutations had either CRD or neutropenia. The presence of microcephaly, found in all patients with VPS13B mutations in this series, was another clinical feature that can help to distinguish between CS and differential diagnoses. Conversely, there was no significant difference for the presence of evocative dysmorphism, obesity and slender extremities.
Therefore, except in young children, these features, in the absence of neutropenia or CRD, are not sufficient to suspect CS. Of note, the assessment of facial gestalt is subjective whereas CRD and neutropenia may be assessed objectively. According to the London Dysmorphology DataBase, around 80 syndromes associate mental retardation and retinopathy, [18] [19] while only a few syndromes associate neutropenia and mental retardation. This explains why the probability of finding a VPS13B mutation in patients with neutropenia (specificity of 95% in our series) in a context of suspected CS is even higher than it is in patients with associated CRD (specificity of 68% in our series)
We also evaluated the clinical criteria used to diagnose CS in our series. Table 3 shows the prevalence of neutropenia in previous series reporting VPS13B mutations.
This prevalence was high except in the series reported by Hennies et al 6 . He found only 10 patients with neutropenia in a series of 18 patients in spite of repeated haematological examinations. These results could not be assigned to any specific ethnic group or genotypephenotype correlation. Table 3 We cannot exclude the possibility of undetected VPS13B mutations and in particular genomic deletions of the VPS13B gene as recently described. 13 Although this hypothesis is very likely in our 2 families in which only one pathogenic mutation was identified, it is unlikely when no pathogenic mutations are identified after genomic sequencing of the entire gene in nonconsanguineous families.
In conclusion, our study showed that CRD and neutropenia appear to be the best predictors for the presence of VPS13B mutations. Given the large size of the gene, and since the probability of finding a VPS13B mutation in the absence of these key features is very low, screening for VPS13B mutations is not recommended unless they are present. Because of the age-dependent onset of CRD, caution should be exercised in young children, in whom followup could be a reasonable alternative. However, VPS13B screening could be offered in such cases when the reproductive context is indicative since there is a 25% risk of recurrence.
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